These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 39012432)

  • 1. Qualitative Interviews Exploring Adverse Event Mitigation Strategies in Adults Receiving Amikacin Liposome Inhalation Suspension.
    Ali J; Wu J; Hassan M; Tsai JH; Touba N; McCarrier K; Ballard M; Chatterjee A
    Pulm Ther; 2024 Sep; 10(3):315-330. PubMed ID: 39012432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early-Phase Adverse Effects and Management of Liposomal Amikacin Inhalation for Refractory
    Morita A; Namkoong H; Yagi K; Asakura T; Hosoya M; Tanaka H; Lee H; Ogawa T; Kusumoto T; Azekawa S; Nakagawara K; Kamata H; Ishii M; Fukunaga K; Ozawa H; Hasegawa N
    Infect Drug Resist; 2022; 15():4001-4011. PubMed ID: 35924016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by
    Griffith DE; Eagle G; Thomson R; Aksamit TR; Hasegawa N; Morimoto K; Addrizzo-Harris DJ; O'Donnell AE; Marras TK; Flume PA; Loebinger MR; Morgan L; Codecasa LR; Hill AT; Ruoss SJ; Yim JJ; Ringshausen FC; Field SK; Philley JV; Wallace RJ; van Ingen J; Coulter C; Nezamis J; Winthrop KL;
    Am J Respir Crit Care Med; 2018 Dec; 198(12):1559-1569. PubMed ID: 30216086
    [No Abstract]   [Full Text] [Related]  

  • 4. Amikacin Liposome Inhalation Suspension in the Real-World Management of Refractory Mycobacterium avium Complex Pulmonary Disease.
    Yanagihara T; Ogata H; Mori A; Kadowaki M; Moriuchi Y; Ishimatsu A; Otsuka J; Taguchi K; Moriwaki A; Yoshida M
    Cureus; 2024 Mar; 16(3):e56622. PubMed ID: 38646349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of initiation of amikacin liposome inhalation suspension on hospitalizations and other healthcare resource utilization measures: a retrospective cohort study in real-world settings.
    Aksamit T; Wu J; Hassan M; Achter E; Chatterjee A
    BMC Pulm Med; 2022 Dec; 22(1):461. PubMed ID: 36463137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amikacin Liposome Inhalation Suspension for
    Winthrop KL; Flume PA; Thomson R; Mange KC; Yuen DW; Ciesielska M; Morimoto K; Ruoss SJ; Codecasa LR; Yim JJ; Marras TK; van Ingen J; Wallace RJ; Brown-Elliott BA; Coulter C; Griffith DE
    Ann Am Thorac Soc; 2021 Jul; 18(7):1147-1157. PubMed ID: 33326356
    [No Abstract]   [Full Text] [Related]  

  • 7. Amikacin Liposome Inhalation Suspension for
    Golia A; Mahmood BR; Fundora Y; Thornby KA; Chahine EB
    Sr Care Pharm; 2020 Apr; 35(4):162-170. PubMed ID: 32192565
    [No Abstract]   [Full Text] [Related]  

  • 8. Amikacin liposome inhalation suspension as a treatment for patients with refractory mycobacterium avium complex lung infection.
    Zhang Y; Hill AT
    Expert Rev Respir Med; 2021 Jun; 15(6):737-744. PubMed ID: 34039231
    [No Abstract]   [Full Text] [Related]  

  • 9. Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease: Sustainability and Durability of Culture Conversion and Safety of Long-term Exposure.
    Griffith DE; Thomson R; Flume PA; Aksamit TR; Field SK; Addrizzo-Harris DJ; Morimoto K; Hoefsloot W; Mange KC; Yuen DW; Ciesielska M; Wallace RJ; van Ingen J; Brown-Elliott BA; Coulter C; Winthrop KL;
    Chest; 2021 Sep; 160(3):831-842. PubMed ID: 33887244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amikacin liposome inhalation suspension for Mycobacterium avium complex pulmonary disease: A subgroup analysis of Japanese patients in the randomized, phase 3, CONVERT study.
    Morimoto K; Nonaka M; Yamazaki Y; Nakagawa T; Takasaki J; Tsuyuguchi K; Kitada S; Jumadilova Z; Yuen DW; Ciesielska M; Hasegawa N
    Respir Investig; 2024 Mar; 62(2):284-290. PubMed ID: 38277865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease.
    Shirley M
    Drugs; 2019 Apr; 79(5):555-562. PubMed ID: 30877642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis and Management of Drug-Induced Interstitial Lung Disease Associated with Amikacin Liposome Inhalation Suspension in Refractory
    Hashimoto K; Nii T; Sumitani H; Yokoyama M; Miyamoto S; Mihashi Y; Nagata Y; Matsuki T; Tsujino K; Miki K; Kida H
    Infect Drug Resist; 2023; 16():6629-6634. PubMed ID: 37840829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nontuberculous mycobacterial lung disease caused by
    van Ingen J; Obradovic M; Hassan M; Lesher B; Hart E; Chatterjee A; Daley CL
    Expert Rev Respir Med; 2021 Nov; 15(11):1387-1401. PubMed ID: 34612115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use.
    Hoy SM
    Clin Drug Investig; 2021 Apr; 41(4):405-412. PubMed ID: 33723805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of drug-induced organizing pneumonia caused by amikacin liposome inhalation suspension.
    Takao D; Takeda K; Takazono T; Ozasa M; Ito Y; Ashizawa N; Hirayama T; Iwanaga N; Takemoto S; Ide S; Tashiro M; Hosogaya N; Kido T; Sakamoto N; Obase Y; Okano S; Izumikawa K; Yanagihara K; Mukae H
    J Infect Chemother; 2023 Aug; 29(8):806-808. PubMed ID: 37098378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults.
    Khan O; Chaudary N
    Drug Des Devel Ther; 2020; 14():2287-2294. PubMed ID: 32606598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Management of Respiratory Adverse Events Associated With Amikacin Liposome Inhalation Suspension: Results From a Patient Survey.
    Swenson C; Lapinel NC; Ali J
    Open Forum Infect Dis; 2020 Apr; 7(4):ofaa079. PubMed ID: 32322600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into Macrophages.
    Zhang J; Leifer F; Rose S; Chun DY; Thaisz J; Herr T; Nashed M; Joseph J; Perkins WR; DiPetrillo K
    Front Microbiol; 2018; 9():915. PubMed ID: 29867826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laryngeal Injury Due to Amikacin Inhalation for Refractory Mycobacterium avium Complex Infection.
    Axiotakis LG; Enver N; Keating CL; Pitman MJ
    Chest; 2021 Apr; 159(4):e185-e187. PubMed ID: 34022015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection.
    Bilton D; Fajac I; Pressler T; Clancy JP; Sands D; Minic P; Cipolli M; Galeva I; Solé A; Quittner AL; Jumadilova Z; Ciesielska M; Konstan MW;
    J Cyst Fibros; 2021 Nov; 20(6):1010-1017. PubMed ID: 34144923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.